Policy and Politics News

Despite research and policy changes from an increasing awareness that access to kidney transplantation is limited for many Americans with kidney failure, researchers found no improvements in access to transplant in 2 decades.

More than 20 kidney care organizations have collaborated on a letter which urges the Biden administration to advance policies for patients with kidney disease, placing special focus on health equity and the COVID-19 pandemic.

Kidney disease is a public health crisis that costs the federal government more than $120 billion per year and threatens to bankrupt the Medicare Trust Fund.

President Donald J. Trump today approved a legislative package that includes lifetime coverage of immunosuppressants for kidney transplant recipients.

The U.S. Senate voted in favor of legislation that extends Medicare coverage of immunosuppressants to all kidney transplant recipients, regardless of age, and ensures these medications are covered for life.

Legislation that offers lifetime immunosuppressive drug coverage for Medicare patients who receive a kidney transplant regardless of age has passed the U.S. House of Representatives.

We are energized by the impact kidney care policy reform can have on the speed of change within nephrology.

Accountable care organizations generated modest savings in the care of Medicare beneficiaries undergoing dialysis when patients received routine care from primary care physicians.

The National Renal Administrators Association sent letters to CMS and the CDC urging the agencies to prioritize issuance of the COVID-19 vaccine to patients with end-stage renal disease and the dialysis clinic staff who provide their care.

On Nov. 20, CMS issued a final rule regarding how the performance of organ procurement organizations is measured in the United States.